A new study published in this month’s issue of the journal Molecular Medicine Reports, and published online by the U.S. National Institute of Health, has found that cannabinoids may prevent cartilage breakdown in those with osteoarthritis.
According to researchers; “A central feature of osteoarthritis (OA) is the loss of articular cartilage, which is primarily attributed to cartilage breakdown.” The current study explored the effects of a synthetic cannabinoid meant to mimic the effects of cannabis-based cannabinoids on preventing this breakdown.
An advisory board voted Wednesday to add eight health conditions — including chronic pain syndrome, autism, osteoarthritis and post-traumatic stress disorder — to the list of illnesses that can be treated by medical marijuana in Illinois.
The state’s Medical Cannabis Advisory Board had expressed frustration last month when Gov. Bruce Rauner’s administration rejected its first 11 suggestions for expanding the list of medical conditions. Osteoarthritis and PTSD were on that earlier list, so Wednesday’s votes reaffirmed the board’s viewpoint and put the matter back in Rauner’s hands.
TheIllinois Medical Cannabis Advisory Board on Monday voted to recommend a variety of medical ailments as conditions that qualify an individual to become a legal medical cannabis patient.
The Board voted 8 to 2 to recommend to the IllinoisDepartment of Health that migraines be added as qualifying conditions for medical cannabis use. The panel voted unanimously to recommend irritable bowel syndrome, post traumatic stress disorder, periphery polyneuropathy and diabetic neuropathy, and voted 7 to 4 to recommend osteoarthritis.
A study published in this month’s issue of the European Journal of Neuroscience has found that cannabinoids may be an effective treatment for osteoarthritis.
According to the study; “Osteoarthritis is a degenerative joint disease associated with articular cartilage degradation. The major clinical outcome of osteoarthritis is a complex pain state that includes both nociceptive and neuropathic mechanisms.”